Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi

Malaria Journal

Table 1 Availability of anti-malarials on day of the survey by retail sector and geographical region

	Retail sector						Geographical region
	Public (n = 24)	%	Private (n = 36)	%	NGO (n = 10)	%	Bujumbura (n = 29)	%	Bururi (n = 24)	%	Kayanza (n = 17)	%a
ACT	21	87.5	12	33.3	9	90.0	15	51.7	11	45.8	16	94.1
AS-AQ^a	21	87.5	12	33.3	9	90.0	15	51.7	11	45.8	16	94.1
Other first-line ACT^b	-	-	2	5.6	-	-	-	-	2	8.3	-	-
Quinine	23	95.8	28	77.8	9	90.0	27	93.1	22	91.7	16	94.1
Quinine injection	17	70.8	23	63.9	9	90.0	21	72.4	16	66.7	12	70.6
Quinine tablets	23	95.8	28	77.8	9	90.0	25	86.2	19	79.2	16	94.1
Both quinine injection and quinine tablets	17	70.8	18	50.0	9	90.0	19	65.5	13	54.2	12	70.6
Non-policy anti-malarials	1	4.2	14	38.9	-	-	9	31.0	3	12.5	3	17.6
Amodiaquine	-	-	1	2.8	-	-	0	0.0	1	4.2	0	0.0
Dihydroartemisinin	-	-	3	8.3	-	-	2	6.9	1	4.2	0	0.0
Halofantrine	1	4.2	10	27.8	-	-	7	24.1	2	8.3	2	11.8
Overall anti-malarial availability	23	95.8	28	77.8	9	90.0	27	93.1	22	91.7	16	94.1
AS-AQ only	1	4.2	0	0.0	1	10.0	0	0.0	1	4.2	1	5.9
Quinine only	2	8.3	13	36.1	1	10.0	7	24.1	9	37.5	0	0.0
Non-policy antimalarials only	0	0.0	1	2.8	0	0.0	1	3.4	0	0.0	0	0.0
AS-AQ+quinine	20	83.3	8	22.2	8	80.0	13	44.8	10	41.7	13	76.5
AS-AQ+non-policy antimalarials	0	0.0	1	2.8	0	0.0	1	3.4	0	0.0	0	0.0
Quinine+non-policy antimalarials	1	4.2	9	25.0	0	0.0	6	20.7	3	12.5	1	5.9
AS-AQ+quinine+non-policy anti-malarials	0	0.0	3	8.3	0	0.0	1	3.4	2	8.3	0	0.0

ACT, artemisinin combination therapy; AS-AQ artesunate-amodiaquine (loose combination)
^a First-line treatment for uncomplicated malaria under Burundi's national antimalarial policy
^b Other first-line ACT antimalarials recommended by the WHO were identified (artemether-lumefantrine and dihydroartemisinin-piperquine)

ISSN: 1475-2875